Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma

Blood

Volumn 122, Issue 12, 2013, Pages 2104-2113

  Amengual, Jennifer E ^a   Clark Garvey, Sean ^a   Kalac, Matko ^a   Scotto, Luigi ^a   Marchi, Enrica ^b   Neylon, Ellen ^a   Johannet, Paul ^a   Wei, Ying ^c   Zain, Jasmine ^a   O'Connor, Owen A ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b LINCOLN MEDICAL AND MENTAL HEALTH CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE ISOENZYME 2; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; NICOTINAMIDE; PENTOSTATIN; PROTEIN BCL 6; PROTEIN P53; ROMIDEPSIN; SIRTUIN; VORINOSTAT; BCOR PROTEIN, HUMAN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; ONCOPROTEIN; REPRESSOR PROTEIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CELL LYSATE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; CYTOTOXICITY; DEACETYLATION; DIARRHEA; DIFFUSE LARGE B CELL LYMPHOMA; DIFFUSE LARGE B-CELL LYMPHOMA CELL LINE; DIZZINESS; DRUG EFFICACY; DRUG POTENTIATION; EDEMA; ENZYME INHIBITION; FAINTNESS; FATIGUE; FEMALE; FEVER; GERMINAL CENTER; HEADACHE; HEART INFARCTION; HERPES ZOSTER; HISTOGRAM; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; HYPOTENSION; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER FAILURE; MARGINAL ZONE LYMPHOMA; METALLIC TASTE; MOUSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ACETYLATION; PRURITUS; RASH; T CELL LYMPHOMA; THORAX PAIN; THROMBOCYTOPENIA; VOMITING; WESTERN BLOTTING; ACETYLATION; ANIMAL; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; IC 50; LARGE CELL LYMPHOMA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME;

ACETYLATION; ADULT; AGED; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; INHIBITORY CONCENTRATION 50; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MICE; MIDDLE AGED; NIACINAMIDE; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; SIRTUINS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887593197     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-485441     Document Type: Article

References (47)

1. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-511.
2. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood. 2005;106(4):1164-1174.
3. Ye BH, Lista F, Lo Coco F, et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science. 1993;262(5134): 747-750.
4. Chang CC, Ye BH, Chaganti RS, Dalla-Favera R. BCL-6, a POZ/zinc-finger protein, is a sequencespecific transcriptional repressor. Proc Natl Acad Sci USA. 1996;93(14):6947-6952.
5. Phan RT, Dalla-Favera R. The BCL6 protooncogene suppresses p53 expression in germinal-centre B cells. Nature. 2004;432(7017): 635-639.
6. Ranuncolo SM, Polo JM, Dierov J, et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol. 2007;8(7):705-714.
7. Pasqualucci L, Bereshchenko O, Niu H, et al. Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. Leuk Lymphoma. 2003;44(suppl 3):S5-S12.
8. published correction appears in Leuk Lymphoma. 2013;54(5):1121]
9. Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol. 2005;6(10):1054-1060.
10. Polo JM, Dell'Oso T, Ranuncolo SM, et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med. 2004;10(12): 1329-1335.
11. Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 2000;408(6810):377-381.
12. Niu H, Ye BH, Dalla-Favera R. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev. 1998;12(13): 1953-1961.
13. Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet. 2002;32(4):606-613.
14. Kovacs JJ, Murphy PJM, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperonedependent activation of glucocorticoid receptor. Mol Cell. 2005;18(5):601-607.
15. Chen Lf, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science. 2001; 293(5535):1653-1657.
16. Parekh S, Polo JM, Shaknovich R, et al. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood. 2007;110(6):2067-2074.
17. Fujita N, Jaye DL, Geigerman C, et al. MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell. 2004;119(1): 75-86.
18. Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001;107(2):149-159.
19. Bernier J, Stratford MR, Denekamp J, et al. Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. Radiother Oncol. 1998;48(2):123-133.
20. Dragovic J, Kim SH, Brown SL, Kim JH. Nicotinamide pharmacokinetics in patients. Radiother Oncol. 1995;36(3):225-228.
21. Nahimana A, Attinger A, Aubry D, et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood. 2009;113(14):3276-3286.
22. Guarente L.Diverse and dynamic functions of the Sir silencing complex. Nat Genet. 1999;23(3):281-285.
23. Bitterman KJ, Anderson RM, Cohen HY, Latorre- Esteves M, Sinclair DA. Inhibition of silencing and accelerated aging by nictinomide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem. 2002;277(47):45099-45107.
24. Heltweg B, Gatbonton T, Schuler AD, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 2006;66(8):4368-4377.
25. O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24(1):166-173.
26. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31-39.
27. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410-5417.
28. Woo S, Gardner ER, Chen X, et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009;15(4):1496-1503.
29. Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res. 2008;14(14):4500-4510.
30. Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol. 2008;19(5):964-969.
31. Marchi E, Paoluzzi L, Scotto L, et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res. 2010; 16(14):3648-3658.
32. Shaffer AL, Lin KI, Kuo TC, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity. 2002;17(1):51-62.
33. Paoluzzi L, Gonen M, Gardner JR, et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood. 2008;111(11): 5350-5358.
34. Scotto L, Kruithof-de Julio M, Paoluzzi L, et al. Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomas. Clin Cancer Res. 2012;18(14):3803-3811.
35. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
36. Zhao L, Wientjes MG, Au JLS. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res. 2004;10(23):7994-8004.
37. Lindstrom ML, Bates DM. Nonlinear mixed effects models for repeated measures data. Biometrics. 1990;46(3):673-687.
38. Welch WJ. Construction of permutation tests. J Am Stat Assoc. 1990;85(411):693-698.
39. Kalac M, Scotto L, Marchi E, et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood. 2011;118(20):5506-5516.
40. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003; 102(12):3871-3879.
41. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578-2585.
42. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277): 88-92.
43. Yang Y, Shaffer AL III, Emre NCT, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21(6):723-737.
44. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/ refractory B-cell malignancies. J Clin Oncol. 2013; 31(1):88-94.
45. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009; 113(24):6069-6076.
46. Wilson WH, Gerecitano JF, Goy A, et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study [abstract]. Blood. 2012;120(21). Abstract 686.
47. Nowakowski GS, LaPlant BR, Reeder C, et al. Combination of lenalidomide with R-CHOP (R2CHOP) is well-tolerated and effective as initial therapy for aggressive B-cell lymphomas-a phase II study [abstract]. Blood. 2012;120(21). Abstract 689.